nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—POMC—kidney cancer	0.435	0.893	CbGaD
Loperamide—ABCB1—kidney cancer	0.0518	0.106	CbGaD
Loperamide—ABCB1—Temsirolimus—kidney cancer	0.023	0.0755	CbGbCtD
Loperamide—CYP2D6—Temsirolimus—kidney cancer	0.0217	0.0711	CbGbCtD
Loperamide—CYP3A4—Everolimus—kidney cancer	0.0204	0.067	CbGbCtD
Loperamide—CYP2C8—Pazopanib—kidney cancer	0.0178	0.0586	CbGbCtD
Loperamide—CYP3A4—Temsirolimus—kidney cancer	0.0138	0.0452	CbGbCtD
Loperamide—CYP2B6—Sorafenib—kidney cancer	0.0137	0.0449	CbGbCtD
Loperamide—CYP2C8—Erlotinib—kidney cancer	0.0127	0.0418	CbGbCtD
Loperamide—ABCB1—Pazopanib—kidney cancer	0.0121	0.0397	CbGbCtD
Loperamide—CYP2C8—Paclitaxel—kidney cancer	0.0117	0.0383	CbGbCtD
Loperamide—CYP2D6—Pazopanib—kidney cancer	0.0114	0.0374	CbGbCtD
Loperamide—ABCB1—Dactinomycin—kidney cancer	0.011	0.0363	CbGbCtD
Loperamide—CYP2C8—Sorafenib—kidney cancer	0.0104	0.034	CbGbCtD
Loperamide—ABCB1—Gemcitabine—kidney cancer	0.00873	0.0287	CbGbCtD
Loperamide—ABCB1—Erlotinib—kidney cancer	0.00862	0.0283	CbGbCtD
Loperamide—POMC—urine—kidney cancer	0.00857	0.258	CbGeAlD
Loperamide—CYP2B6—Doxorubicin—kidney cancer	0.00829	0.0272	CbGbCtD
Loperamide—CYP2D6—Erlotinib—kidney cancer	0.00812	0.0267	CbGbCtD
Loperamide—ABCB1—Paclitaxel—kidney cancer	0.00789	0.0259	CbGbCtD
Loperamide—CYP3A4—Pazopanib—kidney cancer	0.00724	0.0238	CbGbCtD
Loperamide—ABCB1—Sorafenib—kidney cancer	0.00701	0.023	CbGbCtD
Loperamide—ABCB1—Vinblastine—kidney cancer	0.00692	0.0227	CbGbCtD
Loperamide—ABCB1—Vincristine—kidney cancer	0.0068	0.0223	CbGbCtD
Loperamide—CYP2D6—Sorafenib—kidney cancer	0.0066	0.0217	CbGbCtD
Loperamide—CYP2D6—Vinblastine—kidney cancer	0.00652	0.0214	CbGbCtD
Loperamide—ABCB1—Sunitinib—kidney cancer	0.00568	0.0186	CbGbCtD
Loperamide—CYP3A4—Erlotinib—kidney cancer	0.00516	0.017	CbGbCtD
Loperamide—CYP3A4—Paclitaxel—kidney cancer	0.00473	0.0155	CbGbCtD
Loperamide—ABCB1—Doxorubicin—kidney cancer	0.00425	0.014	CbGbCtD
Loperamide—CYP3A4—Sorafenib—kidney cancer	0.0042	0.0138	CbGbCtD
Loperamide—CYP3A4—Vinblastine—kidney cancer	0.00415	0.0136	CbGbCtD
Loperamide—CYP3A4—Vincristine—kidney cancer	0.00408	0.0134	CbGbCtD
Loperamide—CYP2D6—Doxorubicin—kidney cancer	0.00401	0.0132	CbGbCtD
Loperamide—CYP3A4—Sunitinib—kidney cancer	0.0034	0.0112	CbGbCtD
Loperamide—CYP3A4—Doxorubicin—kidney cancer	0.00255	0.00837	CbGbCtD
Loperamide—POMC—renal system—kidney cancer	0.0021	0.0631	CbGeAlD
Loperamide—POMC—kidney—kidney cancer	0.00203	0.061	CbGeAlD
Loperamide—POMC—gonad—kidney cancer	0.00188	0.0566	CbGeAlD
Loperamide—CYP3A4—urine—kidney cancer	0.00131	0.0396	CbGeAlD
Loperamide—CYP2D6—urine—kidney cancer	0.00129	0.0389	CbGeAlD
Loperamide—OPRD1—renal system—kidney cancer	0.00116	0.0348	CbGeAlD
Loperamide—OPRD1—kidney—kidney cancer	0.00112	0.0337	CbGeAlD
Loperamide—CALM3—nephron tubule—kidney cancer	0.000802	0.0241	CbGeAlD
Loperamide—CALM3—cortex of kidney—kidney cancer	0.000687	0.0207	CbGeAlD
Loperamide—CALM3—cardiac atrium—kidney cancer	0.000653	0.0197	CbGeAlD
Loperamide—CALM2—nephron tubule—kidney cancer	0.00063	0.019	CbGeAlD
Loperamide—CALM1—nephron tubule—kidney cancer	0.000627	0.0189	CbGeAlD
Loperamide—CALM2—renal system—kidney cancer	0.000573	0.0172	CbGeAlD
Loperamide—CALM1—renal system—kidney cancer	0.00057	0.0172	CbGeAlD
Loperamide—CALM2—kidney—kidney cancer	0.000554	0.0167	CbGeAlD
Loperamide—CALM1—kidney—kidney cancer	0.000551	0.0166	CbGeAlD
Loperamide—CALM2—cortex of kidney—kidney cancer	0.000539	0.0162	CbGeAlD
Loperamide—CALM1—cortex of kidney—kidney cancer	0.000537	0.0162	CbGeAlD
Loperamide—CALM2—gonad—kidney cancer	0.000514	0.0155	CbGeAlD
Loperamide—CALM2—cardiac atrium—kidney cancer	0.000513	0.0154	CbGeAlD
Loperamide—CALM1—gonad—kidney cancer	0.000511	0.0154	CbGeAlD
Loperamide—CALM1—cardiac atrium—kidney cancer	0.000511	0.0154	CbGeAlD
Loperamide—CYP2C8—renal system—kidney cancer	0.000475	0.0143	CbGeAlD
Loperamide—CYP2B6—nephron tubule—kidney cancer	0.000468	0.0141	CbGeAlD
Loperamide—CYP2C8—kidney—kidney cancer	0.000459	0.0138	CbGeAlD
Loperamide—CYP2B6—renal system—kidney cancer	0.000426	0.0128	CbGeAlD
Loperamide—CYP2B6—kidney—kidney cancer	0.000412	0.0124	CbGeAlD
Loperamide—CYP2B6—gonad—kidney cancer	0.000382	0.0115	CbGeAlD
Loperamide—CYP3A4—renal system—kidney cancer	0.000322	0.00968	CbGeAlD
Loperamide—CYP2D6—renal system—kidney cancer	0.000316	0.00952	CbGeAlD
Loperamide—CYP3A4—kidney—kidney cancer	0.000311	0.00936	CbGeAlD
Loperamide—CYP2D6—kidney—kidney cancer	0.000306	0.00921	CbGeAlD
Loperamide—ABCB1—nephron tubule—kidney cancer	0.00025	0.00754	CbGeAlD
Loperamide—Loss of consciousness—Sorafenib—kidney cancer	0.00024	0.00275	CcSEcCtD
Loperamide—Urinary tract disorder—Gemcitabine—kidney cancer	0.000239	0.00274	CcSEcCtD
Loperamide—Urethral disorder—Gemcitabine—kidney cancer	0.000237	0.00272	CcSEcCtD
Loperamide—Diarrhoea—Temsirolimus—kidney cancer	0.000236	0.00271	CcSEcCtD
Loperamide—Asthenia—Pazopanib—kidney cancer	0.000233	0.00267	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.000231	0.00265	CcSEcCtD
Loperamide—Pruritus—Pazopanib—kidney cancer	0.00023	0.00264	CcSEcCtD
Loperamide—Erythema multiforme—Gemcitabine—kidney cancer	0.000229	0.00262	CcSEcCtD
Loperamide—Urinary retention—Capecitabine—kidney cancer	0.000228	0.00262	CcSEcCtD
Loperamide—Somnolence—Everolimus—kidney cancer	0.000228	0.00262	CcSEcCtD
Loperamide—Dizziness—Temsirolimus—kidney cancer	0.000228	0.00262	CcSEcCtD
Loperamide—ABCB1—renal system—kidney cancer	0.000228	0.00685	CbGeAlD
Loperamide—Dry mouth—Sorafenib—kidney cancer	0.000227	0.00261	CcSEcCtD
Loperamide—Dyspepsia—Everolimus—kidney cancer	0.000226	0.00259	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Paclitaxel—kidney cancer	0.000224	0.00257	CcSEcCtD
Loperamide—Anaphylactic shock—Sorafenib—kidney cancer	0.000223	0.00255	CcSEcCtD
Loperamide—Diarrhoea—Pazopanib—kidney cancer	0.000222	0.00255	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000222	0.00255	CcSEcCtD
Loperamide—Gastrointestinal disorder—Everolimus—kidney cancer	0.000221	0.00254	CcSEcCtD
Loperamide—Fatigue—Everolimus—kidney cancer	0.000221	0.00254	CcSEcCtD
Loperamide—Constipation—Vinblastine—kidney cancer	0.00022	0.00253	CcSEcCtD
Loperamide—ABCB1—kidney—kidney cancer	0.00022	0.00662	CbGeAlD
Loperamide—Abdominal pain upper—Capecitabine—kidney cancer	0.000219	0.00252	CcSEcCtD
Loperamide—Constipation—Everolimus—kidney cancer	0.000219	0.00252	CcSEcCtD
Loperamide—Vomiting—Temsirolimus—kidney cancer	0.000219	0.00252	CcSEcCtD
Loperamide—Dry mouth—Sunitinib—kidney cancer	0.000218	0.00251	CcSEcCtD
Loperamide—Immune system disorder—Gemcitabine—kidney cancer	0.000218	0.00251	CcSEcCtD
Loperamide—Nervous system disorder—Sorafenib—kidney cancer	0.000218	0.0025	CcSEcCtD
Loperamide—Dyspepsia—Erlotinib—kidney cancer	0.000218	0.0025	CcSEcCtD
Loperamide—Rash—Temsirolimus—kidney cancer	0.000217	0.00249	CcSEcCtD
Loperamide—Dermatitis—Temsirolimus—kidney cancer	0.000217	0.00249	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Capecitabine—kidney cancer	0.000216	0.00248	CcSEcCtD
Loperamide—Skin disorder—Sorafenib—kidney cancer	0.000216	0.00248	CcSEcCtD
Loperamide—Headache—Temsirolimus—kidney cancer	0.000216	0.00248	CcSEcCtD
Loperamide—Dizziness—Pazopanib—kidney cancer	0.000215	0.00246	CcSEcCtD
Loperamide—ABCB1—cortex of kidney—kidney cancer	0.000214	0.00645	CbGeAlD
Loperamide—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000214	0.00245	CcSEcCtD
Loperamide—Fatigue—Erlotinib—kidney cancer	0.000213	0.00245	CcSEcCtD
Loperamide—Constipation—Erlotinib—kidney cancer	0.000212	0.00243	CcSEcCtD
Loperamide—Gastrointestinal pain—Vinblastine—kidney cancer	0.00021	0.00242	CcSEcCtD
Loperamide—Nervous system disorder—Sunitinib—kidney cancer	0.00021	0.00241	CcSEcCtD
Loperamide—Gastrointestinal pain—Everolimus—kidney cancer	0.00021	0.00241	CcSEcCtD
Loperamide—Abdominal distension—Capecitabine—kidney cancer	0.000209	0.0024	CcSEcCtD
Loperamide—Discomfort—Dactinomycin—kidney cancer	0.000209	0.0024	CcSEcCtD
Loperamide—Skin disorder—Sunitinib—kidney cancer	0.000208	0.00239	CcSEcCtD
Loperamide—Vomiting—Pazopanib—kidney cancer	0.000206	0.00237	CcSEcCtD
Loperamide—Rash—Pazopanib—kidney cancer	0.000205	0.00235	CcSEcCtD
Loperamide—Nausea—Temsirolimus—kidney cancer	0.000205	0.00235	CcSEcCtD
Loperamide—Dermatitis—Pazopanib—kidney cancer	0.000205	0.00235	CcSEcCtD
Loperamide—ABCB1—gonad—kidney cancer	0.000204	0.00614	CbGeAlD
Loperamide—Abdominal pain—Vinblastine—kidney cancer	0.000203	0.00234	CcSEcCtD
Loperamide—Headache—Pazopanib—kidney cancer	0.000203	0.00233	CcSEcCtD
Loperamide—Abdominal pain—Everolimus—kidney cancer	0.000203	0.00233	CcSEcCtD
Loperamide—Gastrointestinal pain—Erlotinib—kidney cancer	0.000202	0.00232	CcSEcCtD
Loperamide—Urinary tract disorder—Paclitaxel—kidney cancer	0.0002	0.0023	CcSEcCtD
Loperamide—Urethral disorder—Paclitaxel—kidney cancer	0.000198	0.00228	CcSEcCtD
Loperamide—Dyspepsia—Sorafenib—kidney cancer	0.000196	0.00225	CcSEcCtD
Loperamide—Abdominal pain—Erlotinib—kidney cancer	0.000196	0.00224	CcSEcCtD
Loperamide—Nausea—Pazopanib—kidney cancer	0.000193	0.00221	CcSEcCtD
Loperamide—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000192	0.00221	CcSEcCtD
Loperamide—Fatigue—Sorafenib—kidney cancer	0.000192	0.0022	CcSEcCtD
Loperamide—Erythema multiforme—Paclitaxel—kidney cancer	0.000191	0.0022	CcSEcCtD
Loperamide—Constipation—Sorafenib—kidney cancer	0.00019	0.00218	CcSEcCtD
Loperamide—Hypersensitivity—Vinblastine—kidney cancer	0.00019	0.00218	CcSEcCtD
Loperamide—Hypersensitivity—Everolimus—kidney cancer	0.000189	0.00217	CcSEcCtD
Loperamide—Dyspepsia—Sunitinib—kidney cancer	0.000189	0.00216	CcSEcCtD
Loperamide—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000185	0.00212	CcSEcCtD
Loperamide—Asthenia—Vinblastine—kidney cancer	0.000185	0.00212	CcSEcCtD
Loperamide—Fatigue—Sunitinib—kidney cancer	0.000185	0.00212	CcSEcCtD
Loperamide—Asthenia—Everolimus—kidney cancer	0.000184	0.00211	CcSEcCtD
Loperamide—Toremifene—CYP1A1—kidney cancer	0.000184	0.226	CrCbGaD
Loperamide—Stevens-Johnson syndrome—Capecitabine—kidney cancer	0.000184	0.00211	CcSEcCtD
Loperamide—Constipation—Sunitinib—kidney cancer	0.000183	0.0021	CcSEcCtD
Loperamide—Immune system disorder—Paclitaxel—kidney cancer	0.000183	0.0021	CcSEcCtD
Loperamide—Gastrointestinal pain—Sorafenib—kidney cancer	0.000182	0.00209	CcSEcCtD
Loperamide—Pruritus—Everolimus—kidney cancer	0.000181	0.00208	CcSEcCtD
Loperamide—Anaphylactic shock—Vincristine—kidney cancer	0.000181	0.00208	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000178	0.00204	CcSEcCtD
Loperamide—Nervous system disorder—Vincristine—kidney cancer	0.000178	0.00204	CcSEcCtD
Loperamide—Asthenia—Erlotinib—kidney cancer	0.000177	0.00204	CcSEcCtD
Loperamide—Discomfort—Gemcitabine—kidney cancer	0.000177	0.00203	CcSEcCtD
Loperamide—Urticaria—Sorafenib—kidney cancer	0.000177	0.00203	CcSEcCtD
Loperamide—Diarrhoea—Vinblastine—kidney cancer	0.000176	0.00202	CcSEcCtD
Loperamide—Abdominal pain—Sorafenib—kidney cancer	0.000176	0.00202	CcSEcCtD
Loperamide—Diarrhoea—Everolimus—kidney cancer	0.000175	0.00201	CcSEcCtD
Loperamide—Gastrointestinal pain—Sunitinib—kidney cancer	0.000175	0.00201	CcSEcCtD
Loperamide—Pruritus—Erlotinib—kidney cancer	0.000175	0.00201	CcSEcCtD
Loperamide—Fatigue—Dactinomycin—kidney cancer	0.000175	0.00201	CcSEcCtD
Loperamide—Flatulence—Paclitaxel—kidney cancer	0.000174	0.00199	CcSEcCtD
Loperamide—Anaphylactic shock—Gemcitabine—kidney cancer	0.000172	0.00197	CcSEcCtD
Loperamide—Dizziness—Vinblastine—kidney cancer	0.00017	0.00195	CcSEcCtD
Loperamide—Dizziness—Everolimus—kidney cancer	0.00017	0.00195	CcSEcCtD
Loperamide—Abdominal pain—Sunitinib—kidney cancer	0.000169	0.00194	CcSEcCtD
Loperamide—Diarrhoea—Erlotinib—kidney cancer	0.000169	0.00194	CcSEcCtD
Loperamide—Nervous system disorder—Gemcitabine—kidney cancer	0.000169	0.00193	CcSEcCtD
Loperamide—Skin disorder—Gemcitabine—kidney cancer	0.000167	0.00192	CcSEcCtD
Loperamide—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000166	0.0019	CcSEcCtD
Loperamide—Urinary tract disorder—Capecitabine—kidney cancer	0.000164	0.00188	CcSEcCtD
Loperamide—Hypersensitivity—Sorafenib—kidney cancer	0.000164	0.00188	CcSEcCtD
Loperamide—Vomiting—Vinblastine—kidney cancer	0.000164	0.00188	CcSEcCtD
Loperamide—Dizziness—Erlotinib—kidney cancer	0.000164	0.00188	CcSEcCtD
Loperamide—Vomiting—Everolimus—kidney cancer	0.000163	0.00187	CcSEcCtD
Loperamide—Urethral disorder—Capecitabine—kidney cancer	0.000163	0.00187	CcSEcCtD
Loperamide—Dermatitis bullous—Doxorubicin—kidney cancer	0.000162	0.00186	CcSEcCtD
Loperamide—Rash—Everolimus—kidney cancer	0.000162	0.00186	CcSEcCtD
Loperamide—Dermatitis—Everolimus—kidney cancer	0.000162	0.00185	CcSEcCtD
Loperamide—Headache—Vinblastine—kidney cancer	0.000161	0.00185	CcSEcCtD
Loperamide—Angioedema—Paclitaxel—kidney cancer	0.000161	0.00185	CcSEcCtD
Loperamide—Headache—Everolimus—kidney cancer	0.000161	0.00184	CcSEcCtD
Loperamide—Abdominal pain—Dactinomycin—kidney cancer	0.00016	0.00184	CcSEcCtD
Loperamide—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.00016	0.00184	CcSEcCtD
Loperamide—Asthenia—Sorafenib—kidney cancer	0.00016	0.00183	CcSEcCtD
Loperamide—Hypersensitivity—Sunitinib—kidney cancer	0.000158	0.00181	CcSEcCtD
Loperamide—Pruritus—Sorafenib—kidney cancer	0.000157	0.00181	CcSEcCtD
Loperamide—Vomiting—Erlotinib—kidney cancer	0.000157	0.00181	CcSEcCtD
Loperamide—Erythema multiforme—Capecitabine—kidney cancer	0.000157	0.0018	CcSEcCtD
Loperamide—Gastrointestinal disorder—Vincristine—kidney cancer	0.000156	0.00179	CcSEcCtD
Loperamide—Fatigue—Vincristine—kidney cancer	0.000156	0.00179	CcSEcCtD
Loperamide—Rash—Erlotinib—kidney cancer	0.000156	0.00179	CcSEcCtD
Loperamide—Dermatitis—Erlotinib—kidney cancer	0.000156	0.00179	CcSEcCtD
Loperamide—Headache—Erlotinib—kidney cancer	0.000155	0.00178	CcSEcCtD
Loperamide—Loss of consciousness—Paclitaxel—kidney cancer	0.000155	0.00178	CcSEcCtD
Loperamide—Constipation—Vincristine—kidney cancer	0.000155	0.00178	CcSEcCtD
Loperamide—Asthenia—Sunitinib—kidney cancer	0.000154	0.00176	CcSEcCtD
Loperamide—Nausea—Vinblastine—kidney cancer	0.000153	0.00175	CcSEcCtD
Loperamide—Somnolence—Gemcitabine—kidney cancer	0.000153	0.00175	CcSEcCtD
Loperamide—Nausea—Everolimus—kidney cancer	0.000152	0.00175	CcSEcCtD
Loperamide—Diarrhoea—Sorafenib—kidney cancer	0.000152	0.00175	CcSEcCtD
Loperamide—Pruritus—Sunitinib—kidney cancer	0.000152	0.00174	CcSEcCtD
Loperamide—Immune system disorder—Capecitabine—kidney cancer	0.00015	0.00172	CcSEcCtD
Loperamide—Hypersensitivity—Dactinomycin—kidney cancer	0.000149	0.00171	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000149	0.00171	CcSEcCtD
Loperamide—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000148	0.0017	CcSEcCtD
Loperamide—Discomfort—Paclitaxel—kidney cancer	0.000148	0.0017	CcSEcCtD
Loperamide—Fatigue—Gemcitabine—kidney cancer	0.000148	0.0017	CcSEcCtD
Loperamide—Gastrointestinal pain—Vincristine—kidney cancer	0.000148	0.0017	CcSEcCtD
Loperamide—Dizziness—Sorafenib—kidney cancer	0.000147	0.00169	CcSEcCtD
Loperamide—Constipation—Gemcitabine—kidney cancer	0.000147	0.00169	CcSEcCtD
Loperamide—Nausea—Erlotinib—kidney cancer	0.000147	0.00169	CcSEcCtD
Loperamide—Dry mouth—Paclitaxel—kidney cancer	0.000147	0.00168	CcSEcCtD
Loperamide—Diarrhoea—Sunitinib—kidney cancer	0.000147	0.00168	CcSEcCtD
Loperamide—Asthenia—Dactinomycin—kidney cancer	0.000145	0.00167	CcSEcCtD
Loperamide—Anaphylactic shock—Paclitaxel—kidney cancer	0.000144	0.00165	CcSEcCtD
Loperamide—Abdominal pain—Vincristine—kidney cancer	0.000143	0.00164	CcSEcCtD
Loperamide—Flatulence—Capecitabine—kidney cancer	0.000143	0.00164	CcSEcCtD
Loperamide—Dizziness—Sunitinib—kidney cancer	0.000142	0.00163	CcSEcCtD
Loperamide—Vomiting—Sorafenib—kidney cancer	0.000141	0.00162	CcSEcCtD
Loperamide—Abdominal pain upper—Doxorubicin—kidney cancer	0.000141	0.00162	CcSEcCtD
Loperamide—Nervous system disorder—Paclitaxel—kidney cancer	0.000141	0.00162	CcSEcCtD
Loperamide—Rash—Sorafenib—kidney cancer	0.00014	0.00161	CcSEcCtD
Loperamide—Dermatitis—Sorafenib—kidney cancer	0.00014	0.00161	CcSEcCtD
Loperamide—Skin disorder—Paclitaxel—kidney cancer	0.00014	0.0016	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000139	0.0016	CcSEcCtD
Loperamide—Headache—Sorafenib—kidney cancer	0.000139	0.0016	CcSEcCtD
Loperamide—Diarrhoea—Dactinomycin—kidney cancer	0.000139	0.00159	CcSEcCtD
Loperamide—Vomiting—Sunitinib—kidney cancer	0.000136	0.00156	CcSEcCtD
Loperamide—Rash—Sunitinib—kidney cancer	0.000135	0.00155	CcSEcCtD
Loperamide—Dermatitis—Sunitinib—kidney cancer	0.000135	0.00155	CcSEcCtD
Loperamide—Abdominal distension—Doxorubicin—kidney cancer	0.000135	0.00155	CcSEcCtD
Loperamide—Headache—Sunitinib—kidney cancer	0.000134	0.00154	CcSEcCtD
Loperamide—Hypersensitivity—Vincristine—kidney cancer	0.000133	0.00153	CcSEcCtD
Loperamide—Nausea—Sorafenib—kidney cancer	0.000132	0.00152	CcSEcCtD
Loperamide—Asthenia—Vincristine—kidney cancer	0.00013	0.00149	CcSEcCtD
Loperamide—Vomiting—Dactinomycin—kidney cancer	0.000129	0.00148	CcSEcCtD
Loperamide—Somnolence—Paclitaxel—kidney cancer	0.000128	0.00147	CcSEcCtD
Loperamide—Rash—Dactinomycin—kidney cancer	0.000128	0.00147	CcSEcCtD
Loperamide—Nausea—Sunitinib—kidney cancer	0.000127	0.00146	CcSEcCtD
Loperamide—Loss of consciousness—Capecitabine—kidney cancer	0.000127	0.00146	CcSEcCtD
Loperamide—Dyspepsia—Paclitaxel—kidney cancer	0.000127	0.00145	CcSEcCtD
Loperamide—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000124	0.00143	CcSEcCtD
Loperamide—Fatigue—Paclitaxel—kidney cancer	0.000124	0.00142	CcSEcCtD
Loperamide—Diarrhoea—Vincristine—kidney cancer	0.000124	0.00142	CcSEcCtD
Loperamide—Asthenia—Gemcitabine—kidney cancer	0.000123	0.00141	CcSEcCtD
Loperamide—Constipation—Paclitaxel—kidney cancer	0.000123	0.00141	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000122	0.0014	CcSEcCtD
Loperamide—Discomfort—Capecitabine—kidney cancer	0.000122	0.0014	CcSEcCtD
Loperamide—Pruritus—Gemcitabine—kidney cancer	0.000122	0.0014	CcSEcCtD
Loperamide—Dry mouth—Capecitabine—kidney cancer	0.00012	0.00138	CcSEcCtD
Loperamide—Nausea—Dactinomycin—kidney cancer	0.00012	0.00138	CcSEcCtD
Loperamide—Dizziness—Vincristine—kidney cancer	0.00012	0.00137	CcSEcCtD
Loperamide—Drowsiness—Doxorubicin—kidney cancer	0.000119	0.00137	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000118	0.00136	CcSEcCtD
Loperamide—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000118	0.00135	CcSEcCtD
Loperamide—Diarrhoea—Gemcitabine—kidney cancer	0.000118	0.00135	CcSEcCtD
Loperamide—Nervous system disorder—Capecitabine—kidney cancer	0.000116	0.00133	CcSEcCtD
Loperamide—Vomiting—Vincristine—kidney cancer	0.000115	0.00132	CcSEcCtD
Loperamide—Skin disorder—Capecitabine—kidney cancer	0.000115	0.00132	CcSEcCtD
Loperamide—Urticaria—Paclitaxel—kidney cancer	0.000114	0.00131	CcSEcCtD
Loperamide—Rash—Vincristine—kidney cancer	0.000114	0.00131	CcSEcCtD
Loperamide—Dermatitis—Vincristine—kidney cancer	0.000114	0.00131	CcSEcCtD
Loperamide—Abdominal pain—Paclitaxel—kidney cancer	0.000114	0.00131	CcSEcCtD
Loperamide—Headache—Vincristine—kidney cancer	0.000113	0.0013	CcSEcCtD
Loperamide—Haloperidol—CYP1A1—kidney cancer	0.000112	0.138	CrCbGaD
Loperamide—Vomiting—Gemcitabine—kidney cancer	0.000109	0.00125	CcSEcCtD
Loperamide—Rash—Gemcitabine—kidney cancer	0.000108	0.00124	CcSEcCtD
Loperamide—Dermatitis—Gemcitabine—kidney cancer	0.000108	0.00124	CcSEcCtD
Loperamide—Headache—Gemcitabine—kidney cancer	0.000108	0.00124	CcSEcCtD
Loperamide—Nausea—Vincristine—kidney cancer	0.000108	0.00123	CcSEcCtD
Loperamide—Hypersensitivity—Paclitaxel—kidney cancer	0.000106	0.00122	CcSEcCtD
Loperamide—Urinary tract disorder—Doxorubicin—kidney cancer	0.000106	0.00121	CcSEcCtD
Loperamide—Urethral disorder—Doxorubicin—kidney cancer	0.000105	0.00121	CcSEcCtD
Loperamide—Dyspepsia—Capecitabine—kidney cancer	0.000104	0.00119	CcSEcCtD
Loperamide—Asthenia—Paclitaxel—kidney cancer	0.000103	0.00118	CcSEcCtD
Loperamide—Nausea—Gemcitabine—kidney cancer	0.000102	0.00117	CcSEcCtD
Loperamide—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000102	0.00117	CcSEcCtD
Loperamide—Fatigue—Capecitabine—kidney cancer	0.000102	0.00117	CcSEcCtD
Loperamide—Pruritus—Paclitaxel—kidney cancer	0.000102	0.00117	CcSEcCtD
Loperamide—Erythema multiforme—Doxorubicin—kidney cancer	0.000101	0.00116	CcSEcCtD
Loperamide—Constipation—Capecitabine—kidney cancer	0.000101	0.00116	CcSEcCtD
Loperamide—Diarrhoea—Paclitaxel—kidney cancer	9.84e-05	0.00113	CcSEcCtD
Loperamide—Toremifene—ABCB1—kidney cancer	9.76e-05	0.12	CrCbGaD
Loperamide—Immune system disorder—Doxorubicin—kidney cancer	9.68e-05	0.00111	CcSEcCtD
Loperamide—Gastrointestinal pain—Capecitabine—kidney cancer	9.65e-05	0.00111	CcSEcCtD
Loperamide—Dizziness—Paclitaxel—kidney cancer	9.51e-05	0.00109	CcSEcCtD
Loperamide—Urticaria—Capecitabine—kidney cancer	9.38e-05	0.00108	CcSEcCtD
Loperamide—Abdominal pain—Capecitabine—kidney cancer	9.33e-05	0.00107	CcSEcCtD
Loperamide—Flatulence—Doxorubicin—kidney cancer	9.19e-05	0.00105	CcSEcCtD
Loperamide—Vomiting—Paclitaxel—kidney cancer	9.15e-05	0.00105	CcSEcCtD
Loperamide—Rash—Paclitaxel—kidney cancer	9.07e-05	0.00104	CcSEcCtD
Loperamide—Dermatitis—Paclitaxel—kidney cancer	9.06e-05	0.00104	CcSEcCtD
Loperamide—Headache—Paclitaxel—kidney cancer	9.01e-05	0.00103	CcSEcCtD
Loperamide—Hypersensitivity—Capecitabine—kidney cancer	8.7e-05	0.000998	CcSEcCtD
Loperamide—Nausea—Paclitaxel—kidney cancer	8.55e-05	0.000981	CcSEcCtD
Loperamide—Fexofenadine—ABCB1—kidney cancer	8.53e-05	0.105	CrCbGaD
Loperamide—Asthenia—Capecitabine—kidney cancer	8.47e-05	0.000972	CcSEcCtD
Loperamide—Pruritus—Capecitabine—kidney cancer	8.35e-05	0.000959	CcSEcCtD
Loperamide—Loss of consciousness—Doxorubicin—kidney cancer	8.2e-05	0.000941	CcSEcCtD
Loperamide—Diarrhoea—Capecitabine—kidney cancer	8.08e-05	0.000927	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	7.88e-05	0.000905	CcSEcCtD
Loperamide—Discomfort—Doxorubicin—kidney cancer	7.84e-05	0.0009	CcSEcCtD
Loperamide—Dizziness—Capecitabine—kidney cancer	7.81e-05	0.000896	CcSEcCtD
Loperamide—Dry mouth—Doxorubicin—kidney cancer	7.76e-05	0.000891	CcSEcCtD
Loperamide—Anaphylactic shock—Doxorubicin—kidney cancer	7.61e-05	0.000873	CcSEcCtD
Loperamide—Vomiting—Capecitabine—kidney cancer	7.51e-05	0.000862	CcSEcCtD
Loperamide—Nervous system disorder—Doxorubicin—kidney cancer	7.46e-05	0.000857	CcSEcCtD
Loperamide—Rash—Capecitabine—kidney cancer	7.44e-05	0.000854	CcSEcCtD
Loperamide—Dermatitis—Capecitabine—kidney cancer	7.44e-05	0.000854	CcSEcCtD
Loperamide—Headache—Capecitabine—kidney cancer	7.4e-05	0.000849	CcSEcCtD
Loperamide—Skin disorder—Doxorubicin—kidney cancer	7.39e-05	0.000848	CcSEcCtD
Loperamide—Tamoxifen—CYP1A1—kidney cancer	7.34e-05	0.0904	CrCbGaD
Loperamide—Nausea—Capecitabine—kidney cancer	7.01e-05	0.000805	CcSEcCtD
Loperamide—Somnolence—Doxorubicin—kidney cancer	6.77e-05	0.000776	CcSEcCtD
Loperamide—Dyspepsia—Doxorubicin—kidney cancer	6.7e-05	0.000769	CcSEcCtD
Loperamide—Clotrimazole—ABCB1—kidney cancer	6.6e-05	0.0813	CrCbGaD
Loperamide—Gastrointestinal disorder—Doxorubicin—kidney cancer	6.57e-05	0.000754	CcSEcCtD
Loperamide—Fatigue—Doxorubicin—kidney cancer	6.56e-05	0.000753	CcSEcCtD
Loperamide—Constipation—Doxorubicin—kidney cancer	6.51e-05	0.000747	CcSEcCtD
Loperamide—Gastrointestinal pain—Doxorubicin—kidney cancer	6.22e-05	0.000714	CcSEcCtD
Loperamide—Urticaria—Doxorubicin—kidney cancer	6.05e-05	0.000694	CcSEcCtD
Loperamide—Abdominal pain—Doxorubicin—kidney cancer	6.02e-05	0.00069	CcSEcCtD
Loperamide—Haloperidol—ABCB1—kidney cancer	5.94e-05	0.0732	CrCbGaD
Loperamide—Fentanyl—ABCB1—kidney cancer	5.64e-05	0.0695	CrCbGaD
Loperamide—Hypersensitivity—Doxorubicin—kidney cancer	5.61e-05	0.000643	CcSEcCtD
Loperamide—Asthenia—Doxorubicin—kidney cancer	5.46e-05	0.000627	CcSEcCtD
Loperamide—Pruritus—Doxorubicin—kidney cancer	5.38e-05	0.000618	CcSEcCtD
Loperamide—Diarrhoea—Doxorubicin—kidney cancer	5.21e-05	0.000598	CcSEcCtD
Loperamide—Dizziness—Doxorubicin—kidney cancer	5.03e-05	0.000578	CcSEcCtD
Loperamide—Vomiting—Doxorubicin—kidney cancer	4.84e-05	0.000555	CcSEcCtD
Loperamide—Rash—Doxorubicin—kidney cancer	4.8e-05	0.000551	CcSEcCtD
Loperamide—Dermatitis—Doxorubicin—kidney cancer	4.79e-05	0.00055	CcSEcCtD
Loperamide—Headache—Doxorubicin—kidney cancer	4.77e-05	0.000547	CcSEcCtD
Loperamide—Nausea—Doxorubicin—kidney cancer	4.52e-05	0.000519	CcSEcCtD
Loperamide—Tamoxifen—ABCB1—kidney cancer	3.9e-05	0.0481	CrCbGaD
Loperamide—Methadone—ABCB1—kidney cancer	3.87e-05	0.0477	CrCbGaD
Loperamide—OPRM1—Signaling Pathways—MTOR—kidney cancer	3.31e-06	3.78e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MAPK3—kidney cancer	3.3e-06	3.77e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—GSTM1—kidney cancer	3.27e-06	3.73e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—RAF1—kidney cancer	3.25e-06	3.71e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—RELA—kidney cancer	3.24e-06	3.69e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—ERBB2—kidney cancer	3.21e-06	3.67e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—PIK3CA—kidney cancer	3.21e-06	3.66e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—PIK3CA—kidney cancer	3.21e-06	3.66e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MYC—kidney cancer	3.21e-06	3.66e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL2—kidney cancer	3.19e-06	3.64e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—PIK3CA—kidney cancer	3.19e-06	3.64e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—MTOR—kidney cancer	3.17e-06	3.62e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ABCB1—kidney cancer	3.17e-06	3.62e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD4—kidney cancer	3.17e-06	3.61e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ACHE—kidney cancer	3.16e-06	3.61e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GSTT1—kidney cancer	3.16e-06	3.61e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—RAF1—kidney cancer	3.14e-06	3.59e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—RAF1—kidney cancer	3.14e-06	3.59e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MAPK1—kidney cancer	3.14e-06	3.58e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—POMC—kidney cancer	3.13e-06	3.57e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—RELA—kidney cancer	3.13e-06	3.57e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—RELA—kidney cancer	3.13e-06	3.57e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—ERBB2—kidney cancer	3.11e-06	3.55e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—ERBB2—kidney cancer	3.11e-06	3.55e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CDKN1B—kidney cancer	3.11e-06	3.55e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CYP1A1—kidney cancer	3.1e-06	3.53e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL2—kidney cancer	3.08e-06	3.52e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL2—kidney cancer	3.08e-06	3.52e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—PIK3CA—kidney cancer	3.08e-06	3.52e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—PIK3CA—kidney cancer	3.08e-06	3.52e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—GSTM1—kidney cancer	3.08e-06	3.51e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—MTOR—kidney cancer	3.07e-06	3.5e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—MTOR—kidney cancer	3.07e-06	3.5e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD4—kidney cancer	3.06e-06	3.49e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD4—kidney cancer	3.06e-06	3.49e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—VEGFA—kidney cancer	3.06e-06	3.49e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—POMC—kidney cancer	3.05e-06	3.48e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL2—kidney cancer	3.04e-06	3.47e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—HIF1A—kidney cancer	3.04e-06	3.47e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TSC2—kidney cancer	3.03e-06	3.46e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—RAF1—kidney cancer	3e-06	3.42e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—SCARB1—kidney cancer	2.99e-06	3.41e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—CDKN1B—kidney cancer	2.98e-06	3.4e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—ERBB2—kidney cancer	2.97e-06	3.39e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—KRAS—kidney cancer	2.97e-06	3.38e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CCND1—kidney cancer	2.97e-06	3.38e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTGS1—kidney cancer	2.96e-06	3.38e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—JUN—kidney cancer	2.96e-06	3.38e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—POMC—kidney cancer	2.95e-06	3.36e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—POMC—kidney cancer	2.95e-06	3.36e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—HIF1A—kidney cancer	2.94e-06	3.35e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—HIF1A—kidney cancer	2.94e-06	3.35e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CTNNB1—kidney cancer	2.94e-06	3.35e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TSC2—kidney cancer	2.93e-06	3.34e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TSC2—kidney cancer	2.93e-06	3.34e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MTOR—kidney cancer	2.93e-06	3.34e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—CD4—kidney cancer	2.92e-06	3.34e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.92e-06	3.33e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CYP1A1—kidney cancer	2.92e-06	3.33e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL2—kidney cancer	2.91e-06	3.32e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KDR—kidney cancer	2.91e-06	3.31e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PSMD7—kidney cancer	2.9e-06	3.31e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—PTGS2—kidney cancer	2.9e-06	3.31e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—RAF1—kidney cancer	2.9e-06	3.31e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—RAF1—kidney cancer	2.9e-06	3.31e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MAPK3—kidney cancer	2.89e-06	3.3e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—CDKN1B—kidney cancer	2.88e-06	3.29e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—CDKN1B—kidney cancer	2.88e-06	3.29e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—ERBB2—kidney cancer	2.87e-06	3.28e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—ERBB2—kidney cancer	2.87e-06	3.28e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—PTEN—kidney cancer	2.86e-06	3.27e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—JUN—kidney cancer	2.83e-06	3.23e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MTOR—kidney cancer	2.83e-06	3.23e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MTOR—kidney cancer	2.83e-06	3.23e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—CD4—kidney cancer	2.83e-06	3.23e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—CD4—kidney cancer	2.83e-06	3.23e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL2—kidney cancer	2.82e-06	3.22e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL2—kidney cancer	2.82e-06	3.22e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MYC—kidney cancer	2.82e-06	3.21e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—CTNNB1—kidney cancer	2.81e-06	3.21e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KDR—kidney cancer	2.81e-06	3.21e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KDR—kidney cancer	2.81e-06	3.21e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—PTGS2—kidney cancer	2.81e-06	3.2e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—PTGS2—kidney cancer	2.81e-06	3.2e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MAPK1—kidney cancer	2.75e-06	3.14e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—BCHE—kidney cancer	2.75e-06	3.14e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—CDKN1B—kidney cancer	2.75e-06	3.14e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—JUN—kidney cancer	2.74e-06	3.13e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—JUN—kidney cancer	2.74e-06	3.13e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—PTEN—kidney cancer	2.74e-06	3.13e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—PIK3CA—kidney cancer	2.73e-06	3.11e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—CTNNB1—kidney cancer	2.72e-06	3.1e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—CTNNB1—kidney cancer	2.72e-06	3.1e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—SLC5A5—kidney cancer	2.72e-06	3.1e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KIT—kidney cancer	2.68e-06	3.05e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—APC—kidney cancer	2.68e-06	3.05e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—CDKN1B—kidney cancer	2.66e-06	3.03e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—CDKN1B—kidney cancer	2.66e-06	3.03e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—PTEN—kidney cancer	2.65e-06	3.03e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—PTEN—kidney cancer	2.65e-06	3.03e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—POMC—kidney cancer	2.65e-06	3.02e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TP53—kidney cancer	2.64e-06	3.01e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—SLC2A1—kidney cancer	2.63e-06	3e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—KRAS—kidney cancer	2.6e-06	2.97e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—CTNNB1—kidney cancer	2.6e-06	2.96e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—APC—kidney cancer	2.59e-06	2.95e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KIT—kidney cancer	2.59e-06	2.95e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—APC—kidney cancer	2.59e-06	2.95e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KIT—kidney cancer	2.59e-06	2.95e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—VEGFA—kidney cancer	2.59e-06	2.95e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—MAPK3—kidney cancer	2.56e-06	2.92e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—POMC—kidney cancer	2.55e-06	2.91e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—PTEN—kidney cancer	2.53e-06	2.89e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—BRAF—kidney cancer	2.52e-06	2.87e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—CTNNB1—kidney cancer	2.51e-06	2.87e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—CTNNB1—kidney cancer	2.51e-06	2.87e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTGS2—kidney cancer	2.5e-06	2.85e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—MAPK3—kidney cancer	2.48e-06	2.83e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—MAPK3—kidney cancer	2.48e-06	2.83e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—POMC—kidney cancer	2.46e-06	2.81e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—POMC—kidney cancer	2.46e-06	2.81e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—PTEN—kidney cancer	2.45e-06	2.79e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—PTEN—kidney cancer	2.45e-06	2.79e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MAPK3—kidney cancer	2.45e-06	2.79e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—MAPK1—kidney cancer	2.44e-06	2.78e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—BRAF—kidney cancer	2.43e-06	2.78e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—BRAF—kidney cancer	2.43e-06	2.78e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTGS2—kidney cancer	2.43e-06	2.77e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—PIK3CA—kidney cancer	2.39e-06	2.73e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MYC—kidney cancer	2.38e-06	2.71e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—MAPK1—kidney cancer	2.36e-06	2.69e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—MAPK1—kidney cancer	2.36e-06	2.69e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTGS2—kidney cancer	2.35e-06	2.68e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTGS2—kidney cancer	2.35e-06	2.68e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—MAPK3—kidney cancer	2.34e-06	2.67e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MAPK1—kidney cancer	2.33e-06	2.66e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TP53—kidney cancer	2.31e-06	2.64e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—POMC—kidney cancer	2.31e-06	2.63e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—KRAS—kidney cancer	2.3e-06	2.63e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—MAPK3—kidney cancer	2.27e-06	2.58e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—MAPK3—kidney cancer	2.27e-06	2.58e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—MAPK1—kidney cancer	2.23e-06	2.54e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—KRAS—kidney cancer	2.23e-06	2.54e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—KRAS—kidney cancer	2.23e-06	2.54e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—KRAS—kidney cancer	2.2e-06	2.51e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GSTP1—kidney cancer	2.19e-06	2.5e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTEN—kidney cancer	2.18e-06	2.48e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—POMC—kidney cancer	2.18e-06	2.48e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MAPK3—kidney cancer	2.16e-06	2.47e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—MAPK1—kidney cancer	2.16e-06	2.46e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—MAPK1—kidney cancer	2.16e-06	2.46e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTEN—kidney cancer	2.12e-06	2.42e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—PIK3CA—kidney cancer	2.12e-06	2.41e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTGS2—kidney cancer	2.11e-06	2.41e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—KRAS—kidney cancer	2.11e-06	2.4e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MYC—kidney cancer	2.1e-06	2.4e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—RAF1—kidney cancer	2.1e-06	2.4e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MAPK3—kidney cancer	2.09e-06	2.39e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MAPK3—kidney cancer	2.09e-06	2.39e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—RELA—kidney cancer	2.09e-06	2.39e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ERBB2—kidney cancer	2.08e-06	2.37e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ABCB1—kidney cancer	2.07e-06	2.37e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MAPK1—kidney cancer	2.06e-06	2.35e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MTOR—kidney cancer	2.05e-06	2.34e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTEN—kidney cancer	2.05e-06	2.34e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTEN—kidney cancer	2.05e-06	2.34e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—PIK3CA—kidney cancer	2.05e-06	2.34e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—PIK3CA—kidney cancer	2.05e-06	2.34e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—KRAS—kidney cancer	2.04e-06	2.32e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—KRAS—kidney cancer	2.04e-06	2.32e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MYC—kidney cancer	2.03e-06	2.32e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MYC—kidney cancer	2.03e-06	2.32e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—RAF1—kidney cancer	2.03e-06	2.32e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—RAF1—kidney cancer	2.03e-06	2.32e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—RELA—kidney cancer	2.02e-06	2.31e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—RELA—kidney cancer	2.02e-06	2.31e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—PIK3CA—kidney cancer	2.02e-06	2.3e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GSTM1—kidney cancer	2.01e-06	2.3e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ERBB2—kidney cancer	2.01e-06	2.29e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ERBB2—kidney cancer	2.01e-06	2.29e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MAPK1—kidney cancer	1.99e-06	2.27e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MAPK1—kidney cancer	1.99e-06	2.27e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MTOR—kidney cancer	1.98e-06	2.26e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MTOR—kidney cancer	1.98e-06	2.26e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TP53—kidney cancer	1.95e-06	2.23e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—KRAS—kidney cancer	1.94e-06	2.22e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—PIK3CA—kidney cancer	1.93e-06	2.21e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CDKN1B—kidney cancer	1.92e-06	2.2e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.91e-06	2.18e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL2—kidney cancer	1.88e-06	2.15e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—KRAS—kidney cancer	1.88e-06	2.14e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—KRAS—kidney cancer	1.88e-06	2.14e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—PIK3CA—kidney cancer	1.87e-06	2.13e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—PIK3CA—kidney cancer	1.87e-06	2.13e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CDKN1B—kidney cancer	1.86e-06	2.12e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CDKN1B—kidney cancer	1.86e-06	2.12e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTEN—kidney cancer	1.84e-06	2.1e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTGS2—kidney cancer	1.84e-06	2.1e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCND1—kidney cancer	1.84e-06	2.09e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—JUN—kidney cancer	1.83e-06	2.09e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL2—kidney cancer	1.82e-06	2.08e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL2—kidney cancer	1.82e-06	2.08e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CTNNB1—kidney cancer	1.82e-06	2.07e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—PIK3CA—kidney cancer	1.79e-06	2.04e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCND1—kidney cancer	1.78e-06	2.03e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCND1—kidney cancer	1.78e-06	2.03e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—JUN—kidney cancer	1.77e-06	2.02e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—JUN—kidney cancer	1.77e-06	2.02e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PTEN—kidney cancer	1.77e-06	2.02e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CTNNB1—kidney cancer	1.76e-06	2.01e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CTNNB1—kidney cancer	1.76e-06	2.01e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTGS2—kidney cancer	1.74e-06	1.98e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—PIK3CA—kidney cancer	1.73e-06	1.97e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—PIK3CA—kidney cancer	1.73e-06	1.97e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PTEN—kidney cancer	1.71e-06	1.96e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PTEN—kidney cancer	1.71e-06	1.96e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTEN—kidney cancer	1.61e-06	1.83e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—VEGFA—kidney cancer	1.6e-06	1.83e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—VEGFA—kidney cancer	1.55e-06	1.77e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—VEGFA—kidney cancer	1.55e-06	1.77e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PIK3CA—kidney cancer	1.54e-06	1.75e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MAPK3—kidney cancer	1.51e-06	1.73e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTEN—kidney cancer	1.51e-06	1.73e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PIK3CA—kidney cancer	1.5e-06	1.71e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MYC—kidney cancer	1.47e-06	1.68e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MAPK3—kidney cancer	1.46e-06	1.67e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MAPK3—kidney cancer	1.46e-06	1.67e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PIK3CA—kidney cancer	1.45e-06	1.65e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PIK3CA—kidney cancer	1.45e-06	1.65e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MAPK1—kidney cancer	1.44e-06	1.64e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MYC—kidney cancer	1.42e-06	1.63e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MYC—kidney cancer	1.42e-06	1.63e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—POMC—kidney cancer	1.42e-06	1.62e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MAPK1—kidney cancer	1.39e-06	1.59e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MAPK1—kidney cancer	1.39e-06	1.59e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KRAS—kidney cancer	1.36e-06	1.55e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KRAS—kidney cancer	1.32e-06	1.5e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KRAS—kidney cancer	1.32e-06	1.5e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PIK3CA—kidney cancer	1.3e-06	1.48e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PIK3CA—kidney cancer	1.25e-06	1.43e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TP53—kidney cancer	1.21e-06	1.38e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PIK3CA—kidney cancer	1.21e-06	1.38e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PIK3CA—kidney cancer	1.21e-06	1.38e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TP53—kidney cancer	1.17e-06	1.33e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TP53—kidney cancer	1.17e-06	1.33e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTGS2—kidney cancer	1.13e-06	1.29e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3CA—kidney cancer	1.13e-06	1.29e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.07e-06	1.22e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTEN—kidney cancer	9.9e-07	1.13e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3CA—kidney cancer	6.98e-07	7.97e-06	CbGpPWpGaD
